{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:47:03Z","timestamp":1787669223245,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006662","name":"Ardabil University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.ARUMS.REC.1401.068"],"award-info":[{"award-number":["IR.ARUMS.REC.1401.068"]}],"id":[{"id":"10.13039\/501100006662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02966-0","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T07:50:23Z","timestamp":1753861823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Carvedilol sensitizes paclitaxel-resistant gastric cancer AGS cells to paclitaxel: influences on apoptotic regulators, Notch, PI3K\/AKT, ERK1\/2 signaling pathways, and miR-34a expression"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9013-4664","authenticated-orcid":false,"given":"Ali","family":"Niapour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Hosseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavar","family":"Mohebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4025-7997","authenticated-orcid":false,"given":"Haleh","family":"Salati Momeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvin","family":"Tabibzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2966_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"2966_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-020-01219-0","volume":"19","author":"L Yuan","year":"2020","unstructured":"Yuan L, Xu ZY, Ruan SM, Mo S, Qin JJ, Cheng XD. Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Mol Cancer. 2020;19:96. https:\/\/doi.org\/10.1186\/s12943-020-01219-0.","journal-title":"Mol Cancer"},{"key":"2966_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.taap.2016.09.020","volume":"310","author":"V N\u011bmcov\u00e1-F\u00fcrstov\u00e1","year":"2016","unstructured":"N\u011bmcov\u00e1-F\u00fcrstov\u00e1 V, Kopperov\u00e1 D, Balu\u0161\u00edkov\u00e1 K, Ehrlichov\u00e1 M, Brynychov\u00e1 V, V\u00e1clav\u00edkov\u00e1 R, et al. Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. Toxicol Appl Pharmacol. 2016;310:215\u201328. https:\/\/doi.org\/10.1016\/j.taap.2016.09.020.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2966_CR4","doi-asserted-by":"publisher","first-page":"e0160042","DOI":"10.1371\/journal.pone.0160042","volume":"11","author":"F Li","year":"2016","unstructured":"Li F, Zhou X, Zhou H, Jia J, Li L, Zhai S, et al. Reducing both Pgp overexpression and drug efflux with anticancer gold-paclitaxel nanoconjugates. PLoS ONE. 2016;11:e0160042. https:\/\/doi.org\/10.1371\/journal.pone.0160042.","journal-title":"PLoS ONE"},{"key":"2966_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/978-981-13-7647-4_12","volume":"1141","author":"H Amawi","year":"2019","unstructured":"Amawi H, Sim HM, Tiwari AK, Ambudkar SV, Shukla S. ABC transporter-mediated multidrug-resistant cancer. Adv Exp Med Biol. 2019;1141:549\u201380. https:\/\/doi.org\/10.1007\/978-981-13-7647-4_12.","journal-title":"Adv Exp Med Biol"},{"key":"2966_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1055\/s-0042-111821","volume":"66","author":"M Majidinia","year":"2016","unstructured":"Majidinia M, Alizadeh E, Yousefi B, Akbarzadeh M, Zarghami N. Downregulation of Notch signaling pathway as an effective chemosensitizer for cancer treatment. Drug Res (Stuttg). 2016;66:571\u20139. https:\/\/doi.org\/10.1055\/s-0042-111821.","journal-title":"Drug Res (Stuttg)"},{"key":"2966_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00210-022-02217-3","volume":"395","author":"A Niapour","year":"2022","unstructured":"Niapour A, Seyedasli N. Acquisition of paclitaxel resistance modulates the biological traits of gastric cancer AGS cells and facilitates epithelial to mesenchymal transition and angiogenesis. Naunyn Schmiedebergs Arch Pharmacol. 2022;395:515\u201333. https:\/\/doi.org\/10.1007\/s00210-022-02217-3.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2966_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bbcan.2010.06.001","volume":"1806","author":"Z Wang","year":"2010","unstructured":"Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 2010;1806:258\u201367. https:\/\/doi.org\/10.1016\/j.bbcan.2010.06.001.","journal-title":"Biochim Biophys Acta"},{"key":"2966_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-019-1112-1","volume":"19","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li Y, Wang Q, Chen Z, Li X, Wu Z, et al. The PI3K subunits, P110\u03b1 and P110\u03b2 are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol Cancer. 2020;19:10. https:\/\/doi.org\/10.1186\/s12943-019-1112-1.","journal-title":"Mol Cancer"},{"key":"2966_CR10","doi-asserted-by":"publisher","first-page":"e12468","DOI":"10.1016\/j.heliyon.2022.e12468","volume":"8","author":"YH Qi","year":"2022","unstructured":"Qi YH, Yang LZ, Zhou L, Gao LJ, Hou JY, Yan Z, et al. Sympathetic nerve infiltration promotes stomach adenocarcinoma progression via norepinephrine\/beta2-adrenoceptor\/YKL-40 signaling pathway. Heliyon. 2022;8:e12468. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e12468.","journal-title":"Heliyon"},{"key":"2966_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s42003-022-03041-4","volume":"5","author":"JI Hoare","year":"2022","unstructured":"Hoare JI, Osmani B, O\u2019Sullivan EA, Browne A, Campbell N, Metcalf S, et al. Carvedilol targets beta-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy. Commun Biol. 2022;5:106. https:\/\/doi.org\/10.1038\/s42003-022-03041-4.","journal-title":"Commun Biol"},{"key":"2966_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41419-019-2030-2","volume":"10","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhang Y, He Z, Yin K, Li B, Zhang L, et al. Chronic stress promotes gastric cancer progression and metastasis: an essential role for ADRB2. Cell Death Dis. 2019;10:788. https:\/\/doi.org\/10.1038\/s41419-019-2030-2.","journal-title":"Cell Death Dis"},{"key":"2966_CR13","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.4049\/jimmunol.1202364","volume":"190","author":"M Shi","year":"2013","unstructured":"Shi M, Yang Z, Hu M, Liu D, Hu Y, Qian L, et al. Catecholamine-Induced beta2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. J Immunol. 2013;190:5600\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1202364.","journal-title":"J Immunol"},{"key":"2966_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3892\/ijo_00000563","volume":"36","author":"M Erguven","year":"2010","unstructured":"Erguven M, Yazihan N, Aktas E, Sabanci A, Li CJ, Oktem G, et al. Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol. 2010;36:857\u201366. https:\/\/doi.org\/10.3892\/ijo_00000563.","journal-title":"Int J Oncol"},{"key":"2966_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065894","author":"LS Farhoumand","year":"2023","unstructured":"Farhoumand LS, Liu H, Tsimpaki T, Hendgen-Cotta UB, Rassaf T, Bechrakis NE, et al. Blockade of \u00df-adrenergic receptors by nebivolol enables tumor control potential for uveal melanoma in 3D tumor spheroids and 2D cultures. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065894.","journal-title":"Int J Mol Sci"},{"key":"2966_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3892\/ijo.2017.4179","volume":"52","author":"RF Ara\u00fajo De Jr","year":"2018","unstructured":"Ara\u00fajo De Jr RF, Pessoa JB, Cruz LJ, Chan AB, De Castro Miguel E, Cavalcante RS, et al. Apoptosis in human liver carcinoma caused by gold nanoparticles in combination with carvedilol is mediated via modulation of MAPK\/Akt\/mTOR pathway and EGFR\/FAAD proteins. Int J Oncol. 2018;52:189\u2013200. https:\/\/doi.org\/10.3892\/ijo.2017.4179.","journal-title":"Int J Oncol"},{"key":"2966_CR17","doi-asserted-by":"publisher","first-page":"116448","DOI":"10.1016\/j.taap.2023.116448","volume":"465","author":"A Zidan","year":"2023","unstructured":"Zidan A, El Saadany AA, El Maghraby GM, Abdin AA, Hedya SE. Potential cardioprotective and anticancer effects of carvedilol either free or as loaded nanoparticles with or without doxorubicin in solid Ehrlich carcinoma-bearing mice. Toxicol Appl Pharmacol. 2023;465:116448. https:\/\/doi.org\/10.1016\/j.taap.2023.116448.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2966_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/vco.12560","volume":"18","author":"MM Duckett","year":"2020","unstructured":"Duckett MM, Phung SK, Nguyen L, Khammanivong A, Dickerson E, Dusenbery K, et al. The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells. Vet Comp Oncol. 2020;18:128\u201340. https:\/\/doi.org\/10.1111\/vco.12560.","journal-title":"Vet Comp Oncol"},{"key":"2966_CR19","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/s0006-2952(99)00262-2","volume":"58","author":"O Jonsson","year":"1999","unstructured":"Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999;58:1801\u20136. https:\/\/doi.org\/10.1016\/s0006-2952(99)00262-2.","journal-title":"Biochem Pharmacol"},{"key":"2966_CR20","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros-Wanderley MR Jr, das Dores Cruz F, Goncalves Brandao SM, Rigaud VOC, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018;71:2281\u201390. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.049.","journal-title":"J Am Coll Cardiol"},{"key":"2966_CR21","doi-asserted-by":"publisher","first-page":"e23813","DOI":"10.1096\/fj.202400725RR","volume":"38","author":"S Cavalu","year":"2024","unstructured":"Cavalu S, Saber S, Amer AE, Hamad RS, Abdel-Reheim MA, Elmorsy EA, et al. The multifaceted role of beta-blockers in overcoming cancer progression and drug resistance: extending beyond cardiovascular disorders. FASEB J. 2024;38:e23813. https:\/\/doi.org\/10.1096\/fj.202400725RR.","journal-title":"FASEB J"},{"key":"2966_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbrc.2023.03.046","volume":"657","author":"M Zhang","year":"2023","unstructured":"Zhang M, Chen F, Sun X, Huang Y, Zeng Y, Chen J, et al. Sympathetic beta(2)-adrenergic receptor blockade overcomes docetaxel resistance in prostate cancer. Biochem Biophys Res Commun. 2023;657:69\u201379. https:\/\/doi.org\/10.1016\/j.bbrc.2023.03.046.","journal-title":"Biochem Biophys Res Commun"},{"key":"2966_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.tice.2014.11.004","volume":"47","author":"N Niapour","year":"2015","unstructured":"Niapour N, Niapour A, Sheikhkanloui Milan H, Amani M, Salehi H, Najafzadeh N, et al. All trans retinoic acid modulates peripheral nerve fibroblasts viability and apoptosis. Tissue Cell. 2015;47:61\u20135. https:\/\/doi.org\/10.1016\/j.tice.2014.11.004.","journal-title":"Tissue Cell"},{"key":"2966_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10616-018-0199-3","volume":"70","author":"E Patrad","year":"2018","unstructured":"Patrad E, Niapour A, Farassati F, Amani M. Combination treatment of all-trans retinoic acid (ATRA) and \u03b3-secretase inhibitor (DAPT) cause growth inhibition and apoptosis induction in the human gastric cancer cell line. Cytotechnology. 2018;70:865\u201377. https:\/\/doi.org\/10.1007\/s10616-018-0199-3.","journal-title":"Cytotechnology"},{"key":"2966_CR25","doi-asserted-by":"publisher","first-page":"22413","DOI":"10.1007\/s11356-022-23510-x","volume":"30","author":"A Niapour","year":"2023","unstructured":"Niapour A, Miran M, Seyedasli N, Norouzi F. Anti-angiogenic effects of aqueous extract from Agrostemma githago L. seed in human umbilical vein endothelial cells via regulating Notch\/VEGF, MMP2\/9, ANG2, and VEGFR2. Environ Sci Pollut Res Int. 2023;30:22413\u201329. https:\/\/doi.org\/10.1007\/s11356-022-23510-x.","journal-title":"Environ Sci Pollut Res Int"},{"key":"2966_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797. https:\/\/doi.org\/10.1038\/s41419-020-02998-6.","journal-title":"Cell Death Dis"},{"key":"2966_CR27","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.apsb.2022.10.002","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ye B, Chen Z, Chen ZS. Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers. Acta Pharm Sin B. 2023;13:982\u201397. https:\/\/doi.org\/10.1016\/j.apsb.2022.10.002.","journal-title":"Acta Pharm Sin B"},{"key":"2966_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","volume":"130","author":"FR Weth","year":"2024","unstructured":"Weth FR, Hoggarth GB, Weth AF, Paterson E, White MPJ, Tan ST, et al. Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. Br J Cancer. 2024;130:703\u201315. https:\/\/doi.org\/10.1038\/s41416-023-02502-9.","journal-title":"Br J Cancer"},{"key":"2966_CR29","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/cas.13275","volume":"108","author":"H Chen","year":"2017","unstructured":"Chen H, Zhang W, Cheng X, Guo L, Xie S, Ma Y, et al. \u03b22-AR activation induces chemoresistance by modulating p53 acetylation through upregulating Sirt1 in cervical cancer cells. Cancer Sci. 2017;108:1310\u20137. https:\/\/doi.org\/10.1111\/cas.13275.","journal-title":"Cancer Sci"},{"key":"2966_CR30","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/bjc.2013.205","volume":"108","author":"E Pasquier","year":"2013","unstructured":"Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, et al. \u03b2-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer. 2013;108:2485\u201394. https:\/\/doi.org\/10.1038\/bjc.2013.205.","journal-title":"Br J Cancer"},{"key":"2966_CR31","doi-asserted-by":"publisher","first-page":"10465","DOI":"10.1038\/s41598-020-67342-6","volume":"10","author":"L Porcelli","year":"2020","unstructured":"Porcelli L, Garofoli M, Di Fonte R, Fucci L, Volpicella M, Strippoli S, et al. The beta-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. Sci Rep. 2020;10:10465. https:\/\/doi.org\/10.1038\/s41598-020-67342-6.","journal-title":"Sci Rep"},{"key":"2966_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1349-7006.2003.tb01356.x","volume":"94","author":"M Kakumoto","year":"2003","unstructured":"Kakumoto M, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, et al. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci. 2003;94:81\u20136. https:\/\/doi.org\/10.1111\/j.1349-7006.2003.tb01356.x.","journal-title":"Cancer Sci"},{"key":"2966_CR33","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1007\/s00210-023-02914-7","volume":"397","author":"M Khoshnavay Foumani","year":"2024","unstructured":"Khoshnavay Foumani M, Amirshahrokhi K, Namjoo Z, Niapour A. Carvedilol attenuates inflammatory reactions of lipopolysaccharide-stimulated BV2 cells and modulates M1\/M2 polarization of microglia via regulating NLRP3, Notch, and PPAR-gamma signaling pathways. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:4727\u201336. https:\/\/doi.org\/10.1007\/s00210-023-02914-7.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2966_CR34","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41419-020-03056-x","volume":"11","author":"L Mele","year":"2020","unstructured":"Mele L, Del Vecchio V, Marampon F, Regad T, Wagner S, Mosca L, et al. \u03b22-AR blockade potentiates MEK1\/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism. Cell Death Dis. 2020;11:850. https:\/\/doi.org\/10.1038\/s41419-020-03056-x.","journal-title":"Cell Death Dis"},{"key":"2966_CR35","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.21873\/anticanres.15437","volume":"41","author":"C Jiang","year":"2021","unstructured":"Jiang C, Zheng T, Park JH, Lee JS, Oh Y, Kundu A, et al. Sensitization effects of repurposed blood pressure-regulating drugs on drug-resistant cancer cells. Anticancer Res. 2021;41:6179\u201390. https:\/\/doi.org\/10.21873\/anticanres.15437.","journal-title":"Anticancer Res"},{"key":"2966_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.pharep.2017.11.007","volume":"70","author":"GI Dos Santos","year":"2018","unstructured":"Dos Santos GI, Ladislau-Magescky T, Tessarollo NG, Dos Santos DZ, Gimba ERP, Sternberg C, et al. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines. Pharmacol Rep. 2018;70:409\u201317. https:\/\/doi.org\/10.1016\/j.pharep.2017.11.007.","journal-title":"Pharmacol Rep"},{"key":"2966_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/1471-2407-8-266","volume":"8","author":"Q Ji","year":"2008","unstructured":"Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008;8:266. https:\/\/doi.org\/10.1186\/1471-2407-8-266.","journal-title":"BMC Cancer"},{"key":"2966_CR38","doi-asserted-by":"publisher","first-page":"768918","DOI":"10.3389\/fonc.2021.768918","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Ao X, Ji G, Zhang Y, Yu W, Wang J. Mechanisms of action and clinical implications of microRNAs in the drug resistance of gastric cancer. Front Oncol. 2021;11:768918. https:\/\/doi.org\/10.3389\/fonc.2021.768918.","journal-title":"Front Oncol"},{"key":"2966_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194723","author":"J Fu","year":"2023","unstructured":"Fu J, Imani S, Wu MY, Wu RC. MicroRNA-34 family in cancers: role, mechanism, and therapeutic potential. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15194723.","journal-title":"Cancers (Basel)"},{"key":"2966_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3748\/wjg.v26.i5.499","volume":"26","author":"H Zheng","year":"2020","unstructured":"Zheng H, Wang JJ, Yang XR, Yu YL. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells. World J Gastroenterol. 2020;26:499\u2013513. https:\/\/doi.org\/10.3748\/wjg.v26.i5.499.","journal-title":"World J Gastroenterol"},{"key":"2966_CR41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/cbdd.14240","volume":"102","author":"B Mortezagholi","year":"2023","unstructured":"Mortezagholi B, Nasiri K, Movahed E, Dadgar E, Nejati ST, Hassani P, et al. MiR-34 by targeting p53 induces apoptosis and DNA damage in paclitaxel-resistant human oral squamous carcinoma cells. Chem Biol Drug Des. 2023;102:285\u201391. https:\/\/doi.org\/10.1111\/cbdd.14240.","journal-title":"Chem Biol Drug Des"},{"key":"2966_CR42","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1097\/MPA.0000000000001920","volume":"50","author":"Y Pan","year":"2021","unstructured":"Pan Y, Li K, Tao X, Zhao Y, Chen Q, Li N, et al. MicroRNA-34a alleviates gemcitabine resistance in pancreatic cancer by repression of cancer stem cell renewal. Pancreas. 2021;50:1260\u20136. https:\/\/doi.org\/10.1097\/MPA.0000000000001920.","journal-title":"Pancreas"},{"key":"2966_CR43","doi-asserted-by":"publisher","first-page":"964934","DOI":"10.3389\/fonc.2022.964934","volume":"12","author":"L Yong","year":"2022","unstructured":"Yong L, Tang S, Yu H, Zhang H, Zhang Y, Wan Y, et al. The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer. Front Oncol. 2022;12:964934. https:\/\/doi.org\/10.3389\/fonc.2022.964934.","journal-title":"Front Oncol"},{"key":"2966_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3727\/096504015X14500513118029","volume":"23","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Tan BB, Li Y, Fan LQ, Yang PG, Tian Y. Enhancement of drug sensitivity by knockdown of HIF-1alpha in gastric carcinoma cells. Oncol Res. 2016;23:129\u201336. https:\/\/doi.org\/10.3727\/096504015X14500513118029.","journal-title":"Oncol Res"},{"key":"2966_CR45","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2147\/OTT.S82835","volume":"8","author":"Y Lv","year":"2015","unstructured":"Lv Y, Zhao S, Han J, Zheng L, Yang Z, Zhao L. Hypoxia-inducible factor-1alpha induces multidrug resistance protein in colon cancer. Onco Targets Ther. 2015;8:1941\u20138. https:\/\/doi.org\/10.2147\/OTT.S82835.","journal-title":"Onco Targets Ther"},{"key":"2966_CR46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2016.01.009","volume":"373","author":"Z Ai","year":"2016","unstructured":"Ai Z, Lu Y, Qiu S, Fan Z. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett. 2016;373:36\u201344. https:\/\/doi.org\/10.1016\/j.canlet.2016.01.009.","journal-title":"Cancer Lett"},{"key":"2966_CR47","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.18632\/oncotarget.3241","volume":"6","author":"Z Yang","year":"2015","unstructured":"Yang Z, Guo L, Liu D, Sun L, Chen H, Deng Q, et al. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6\/STAT3\/Jagged-1\/Notch positive feedback loop. Oncotarget. 2015;6:5072\u201387. https:\/\/doi.org\/10.18632\/oncotarget.3241.","journal-title":"Oncotarget"},{"key":"2966_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012509","author":"O Kachanova","year":"2022","unstructured":"Kachanova O, Lobov A, Malashicheva A. The role of the Notch signaling pathway in recovery of cardiac function after myocardial infarction. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232012509.","journal-title":"Int J Mol Sci"},{"key":"2966_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41419-017-0132-2","volume":"9","author":"D Chen","year":"2018","unstructured":"Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li Z, et al. Dual PI3K\/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K\/Akt\/mTOR pathway. Cell Death Dis. 2018;9:123. https:\/\/doi.org\/10.1038\/s41419-017-0132-2.","journal-title":"Cell Death Dis"},{"key":"2966_CR50","doi-asserted-by":"publisher","first-page":"72990","DOI":"10.18632\/oncotarget.12166","volume":"7","author":"SQ Wang","year":"2016","unstructured":"Wang SQ, Wang C, Chang LM, Zhou KR, Wang JW, Ke Y, et al. Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN\/PI3K\/Akt pathway. Oncotarget. 2016;7:72990\u20133002. https:\/\/doi.org\/10.18632\/oncotarget.12166.","journal-title":"Oncotarget"},{"key":"2966_CR51","first-page":"1449","volume":"7","author":"G Wu","year":"2014","unstructured":"Wu G, Qin XQ, Guo JJ, Li TY, Chen JH. AKT\/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 2014;7:1449\u201358.","journal-title":"Int J Clin Exp Pathol"},{"key":"2966_CR52","doi-asserted-by":"publisher","first-page":"e16051","DOI":"10.1200\/JCO.2023.41.16_suppl.e16051","volume":"41","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Pal R, Mistry T, Kumar Sahoo P, Mahata S, Sarkar S, et al. Effect of overexpression of ERK1\/2 and MDR1 on chemoresistance in advanced gastric cancer patients. J Clin Oncol. 2023;41:e16051. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16051.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02966-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02966-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02966-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T04:47:40Z","timestamp":1756442860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02966-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":52,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2966"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02966-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no relevant financial or non-financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was approved by the ethical committee of Ardabil University of Medical Sciences (IR.ARUMS.REC.1401.068).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"392"}}